Eylea vs Izervay
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Eylea | US Izervay | |
|---|---|---|
| Generic name | aflibercept | avacincaptad pegol |
| Drug class | VEGF Inhibitor (Eye Injection) | Complement C5 Inhibitor |
| Treats | Wet macular degeneration, diabetic eye disease | Geographic atrophy (advanced dry AMD) |
| Category | Eye Health | Eye Health |
| Manufacturer | Regeneron | Astellas Pharma |
| Year approved | 2011 | 2023 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $90M | — |
| Common side effects | Eye floaters, Eye pain, Increased eye pressure, Bleeding in the eye | Bleeding in the eye, Increased eye pressure, Floaters, Risk of eye infection |
Frequently asked questions
Is Eylea or Izervay better?
Neither is universally "better." Eylea (aflibercept) and Izervay (avacincaptad pegol) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Eylea and Izervay?
Eylea is a VEGF Inhibitor (Eye Injection) made by Regeneron, while Izervay is a Complement C5 Inhibitor made by Astellas Pharma. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Eylea has the larger estimated TV advertising budget of the two.